Accrued Expenses and Other Liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued Expenses, summarized by major category, as of June 30, 2023 and December 31, 2022 consist of the following:

	June 30, 2023		December 31, 2022
Payroll and incentives	$	1,027	$	1,705
General and administrative expenses		257		455
Research and development expenses		88		130
Deferred revenue *		-		721
Other deferred liabilities **		-		88
Total	$	1,372	$	3,099

*	At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
**	At December 31, 2022, the balances of $88 related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).